Figure 6.

MAPT^P301S mice add more ASPA⁺ mature oligodendrocytes to the hippocampus and fimbria than control mice between 5 and 6 months of age. (a‐h) Confocal images showing ASPA (red), PDGFRα (blue) and YFP (green) in the hippocampus of P60 + 120 Pdgfrα‐CreER^T2:: Rosa26‐YFP (control; a‐d) and Pdgfrα‐CreER^T2:: Rosa26‐YFP:: Prnp‐MAPT^P301S (MAPT^P301S ; e‐h) mice at ~Bregma −1.7. (m) Quantification of the density of all YFP⁺ cells that are PDGFRα‐negative in the hippocampus of P60 + 120 control and MAPT^P301S mice, including those that are YFP⁺ PDGFRα‐negative ASPA‐negative premyelinating oligodendrocytes versus YFP⁺ PDGFRα‐negative ASPA⁺ mature oligodendrocytes. [two‐way ANOVA, genotype: F (1, 12) = 120.5, p < .0001; cell type: F (2, 12) = 79.72, p < .0001; interaction: F (2, 12) = 25.19, p < .0001]. (n) Quantification of the density of all YFP⁺ cells that are PDGFRα‐negative in the fimbria of P60 + 120 control and MAPT^P301S mice, including those that are YFP⁺ PDGFRα‐negative ASPA‐negative premyelinating oligodendrocytes versus YFP⁺ PDGFRα‐negative ASPA⁺ mature oligodendrocytes. [two‐way ANOVA, genotype: F (1, 12) = 40.81, p < .0001; age: F (2, 12) = 15.27, p = .0005; interaction: F (2, 12) = 5.46, p = .02]. Asterisks indicate significant differences identified by Bonferroni post hoc analysis, **p < .01, ***p < .001, ****p < .0001. Scale bars represent 35µm